Skip to content
Use caution Drug recall · FDA · Published September 25, 2015

Recall: Boehringer Ingelheim Furosemide 20 mg Tablets Due to CGMP Deviations

Boehringer Ingelheim Roxane recalls specific lots of Furosemide Tablets USP 20 mg due to manufacturing errors involving incorrect active ingredients.

🇺🇸 FDA recall #D-0011-2016DrugBoehringer Ingelheim Roxane ›
Take action

Contact the company

Recalling firmBoehringer Ingelheim Roxane Inc1809 Wilson Rd · Columbus, OH 43228-9579
✎ GovInfoNow plain-language explainer

Boehringer Ingelheim Roxane Inc is recalling Furosemide Tablets USP, 20 mg, in 1000-count bottles due to Current Good Manufacturing Practice (CGMP) deviations. The company inadvertently used the active pharmaceutical ingredient intended for an oral solution instead of the correct one for the tablets. This affects specific lots distributed nationwide and in Puerto Rico. Read more at govinfonow.com/recall/43617-boehringer-ingelheim-roxane-inc-recalls-furosemide-tablets-usp-20-mg.

Source Summary by GovInfoNow · govinfonow.com/recall/43617-boehringer-ingelheim-roxane-inc-recalls-furosemide-tablets-usp-20-mg · Updated October 12, 2026 · FDA enforcement record: FDA #D-0011-2016

Cite this page

“Recall: Boehringer Ingelheim Furosemide 20 mg Tablets Due to CGMP Deviations.” GovInfoNow, updated October 12, 2026. https://govinfonow.com/recall/43617-boehringer-ingelheim-roxane-inc-recalls-furosemide-tablets-usp-20-mg. Based on FDA recall #D-0011-2016 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0011-2016%22&limit=1).

The FDA announced on September 25, 2015, that Boehringer Ingelheim Roxane Inc voluntarily recalled Furosemide Tablets USP, 20 mg due to CGMP deviations involving the inadvertent use of an active pharmaceutical ingredient intended for oral solution. The recall affects 11,110 bottles distributed nationwide and in Puerto Rico.

How to tell if you have it

  • Brand: Boehringer Ingelheim Roxane
  • Product: Furosemide Tablets USP, 20 mg, 1000-count bottle
  • NDC: 0054-4297-31
  • UPC: 3 0054-4297-31 8 (or 00300544297318)
  • Lot codes: 559660P, 559661P
  • Expiration date: 03/17

The hazard

The firm used the active pharmaceutical ingredient intended for furosemide oral solution USP to manufacture the recalled tablets. This constitutes a CGMP deviation.

Context

GovInfoNow's records show Boehringer Ingelheim Roxane Inc has 12 other recalls on record since 2012-11-05. Other recent recalls of similar products include Combivent Respimat Recall (2015-07-24), Roxane Recalls Acarbose 50mg Tablets Due to Low Potency (2015-04-02), and Roxane Recalls Oxycodone Oral Solution Due to Stability Failure (2014-07-28). Other recent recalls of similar products include Leading Pharma Recalls Furosemide 80mg Due to Impurity (2026-03-20) and Wells Pharma fentanyl injectable solution recall due to manufacturing deviations (2026-04-01).

How to tell if you have this one

Check your medication bottle for the following details: Product name 'FUROSEMIDE Tablets USP, 20 mg', NDC 0054-4297-31, UPC 3 0054-4297-31 8. Verify the lot number is either 559660P or 559661P and the expiration date is 03/17.

  • Brand
    Boehringer Ingelheim Roxane
  • Product
    FUROSEMIDE Tablets USP, 20 mg, 1000-count bottle, Rx only, Boehringer Ingelheim Roxane Laboratories, Roxane
  • Category
    Drug
FDA recall event · 2 products

All 2 products in this recall

FDA lists each product line separately under one recall event. Check your product description, lot or code numbers against each row. Every row shares the hazard and remedy on this page.

  • Classification
    Class III
  • Status
    Terminated
  • Distribution
    Nationwide and Puerto Rico
  • NDC
    0054-4297-31, 0054-4297-25, 0054-8297-25, 0054-4299-31, 0054-4299-25, 0054-8299-25, 0054-4301-29, 0054-4301-25, 0054-8301-25, 0054-3298-63, 0054-3294-50, 0054-3294-46
Recall numberProduct, codes & lotsQuantity
D-0011-2016FUROSEMIDE Tablets USP, 20 mg, 1000-count bottle, Rx only, Boehringer Ingelheim Roxane Laboratories, Roxane Laboratories, Inc., Columbus, OH 43216, NDC 0054-4297-31, UPC 3 0054-4297-31 8.; Lot #: 559660P, 559661P, Exp 03/1711,110 bottles
D-0012-2016FUROSEMIDE Tablets USP, 40 mg, 1000-count bottle, Rx only, Boehringer Ingelheim Roxane Laboratories, Roxane Laboratories, Inc., Columbus, OH 43216, NDC 0054-4299-31, UPC 3 0054-4299-31 2.; Lot #: 559310P, Exp 02/17; 559664B, Exp 04/175,160 bottles
Based on the official FDA remedy

What to do — step by step

  1. Check Your Medication

    Verify if your bottle matches the recalled NDC, UPC, lot numbers (559660P or 559661P), and expiration date of 03/17.

  2. Contact Your Pharmacist

    If you have the recalled product, contact your pharmacist or healthcare provider immediately for guidance on replacement or disposal.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFLPuerto Rico: yesPR

FDA distribution: “Nationwide and Puerto Rico” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA terminated this recall 5 months after the firm started it.

1. Firm started the recall: Sep 25, 201512. FDA classified it Class III: Oct 9, 201523. Published in FDA’s Enforcement Report: Oct 21, 201534. FDA terminated the recall: Feb 19, 2016420152016
  1. Firm started the recall
  2. FDA classified it Class III
  3. Published in FDA’s Enforcement Report
  4. FDA terminated the recall

Dates from the agency record only; steps without a date are left out.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0011-2016 (September 25, 2015) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0011-2016 to see it in context.
  • Plain-language summary written by qwen3.6:35b-a3b on October 12, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA